Tumor Endothelial ELTD1 as a Predictive Marker for Treatment of Renal Cancer Patients With Sunitinib

BMC Cancer - United Kingdom
doi 10.1186/s12885-020-06770-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Journal of Cancer
Oncology
2017English

Dynamic Changes of Live/Apoptotic Circulating Tumour Cells as Predictive Marker of Response to Sunitinib in Metastatic Renal Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study

Diagnostics
Clinical Biochemistry
2020English

Sunitinib for Advanced Renal Cell Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study

Clinical Genitourinary Cancer
OncologyUrology
2016English

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Clinical Genitourinary Cancer
OncologyUrology
2014English

Genetic Polymorphisms as Predictive Biomarker of Survival in Patients With Gastrointestinal Stromal Tumors Treated With Sunitinib

Pharmacogenomics Journal
Molecular MedicineGeneticsPharmacology
2017English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Promoter Methylation of TRIM9 as a Marker for Detection of Circulating Tumor DNA in Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy